Deep Brain Stimulation for Tinnitus
Deep Brain Stimulation for Refractory Tinnitus
1 other identifier
interventional
6
1 country
1
Brief Summary
Tinnitus is the perception of a sound in the absence of an audible source. Currently up to 15% of the general population suffers chronically from tinnitus. The most severe degree of tinnitus ís experienced by 2.4% of the population and is associated with insomnia, depression; anxiety and even suicide. Up to date there is no effective standard therapy. Current therapies mostly focus on treating the distress caused by tinnitus instead of reducing the actual phantom sound. Nevertheless, many patients do not benefit from the current approaches and become severe and chronic tinnitus sufferers. In these patients neuromodulation-based treatments can be a promising option. Tinnitus perception is associated with many complex changes in several different brain structures. The general accepted hypothesis is that neuronal changes occur in both auditory and non-auditory brain structures, most often as a compensating mechanism on reduced input from the auditory nerve caused by cochlear hair cell damage. These central neuronal changes include an increase in spontaneous firing rate, synchronized activity, bursting activity and tonotopic reorganization. In high-frequency deep brain stimulation (DBS) a reversible lesion-like effect is mimicked. From findings in Parkinson's disease patients who also had tinnitus and were treated with DBS, it is known that stimulation can alter or even completely diminish perception of tinnitus. It can be expected that modulation of specific structures within the complex tinnitus pathways can disrupt pathological neuronal activity and thereby alter tinnitus perception or distress caused by this phantom sensation. The investigators found in animal studies that DBS in the central auditory pathway can indeed significantly decrease tinnitus-like behavior. In a questionnaire study the investigators found that around one-fifth of the patients would be reasonably willing to accept invasive treatments and one-fifth would be fully willing to undergo invasive treatment like DBS. Based on preclinical studies and human case studies, the investigators expect that DBS of the central auditory pathway will inhibit tinnitus perception and distress caused by this phantom sensation. Based on studies performed within Maastricht University Medical Center (MUMC), the investigators selected the medial geniculate body of the thalamus (MGB) as the most potential target to treat tinnitus with DBS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 7, 2019
CompletedFirst Posted
Study publicly available on registry
June 6, 2019
CompletedStudy Start
First participant enrolled
January 6, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2024
CompletedJuly 18, 2025
July 1, 2025
3 years
March 7, 2019
July 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change over time of the score on the Tinnitus Functional Index
A validated questionnaire which assesses the impact of tinnitus on a patient measured on multiple time points to measure a change over time. The TFI score can range from 0-100, higher values indicate more tinnitus burden. When a patient scores 54 or higher the tinnitus is considered to be a major problem.
Week 1, week 20, week 26, week 33, week 60
Secondary Outcomes (19)
VAS Loudness
Week 1, week 12, week 20, week 26, week 33, week 60
VAS Burden
Week 1, week 12, week 20, week 26, week 33, week 60
15 word memory test
Week 1, week 27, week 34, week 60
Boston naming test
Week 1, week 27, week 34, week 60
Stroop Color and Word Test
Week 1, week 27, week 34, week 60
- +14 more secondary outcomes
Study Arms (2)
ON-OFF
EXPERIMENTALPatients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
OFF-ON
EXPERIMENTALPatients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
Interventions
High frequency deep brain stimulation in the medial geniculate body of the thalamus.
Eligibility Criteria
You may qualify if:
- Medically refractory tinnitus. Patient does not respond to available tinnitus treatments (hearing aids, cognitive treatments) and is thoroughly evaluated by the multidisciplinary tinnitus team in MUMC. Thus patients do not respond to both of the following treatments (i.e. TQ is still ≥ 47):
- Hearing aids (except if hearing is normal)
- Evidence-based cognitive treatment in Hoensbroek (Cima et al., 2012) or a similar version of this treatment in the MUMC
- Minimum age 18 years, maximum age 69 years.
- Experiencing tinnitus which is:
- Not pulsatile
- Unilateral or bilateral
- Severe tinnitus (based on the TQ score ≥ 47)
- Chronic and stable (present \> 2 years and stable \> 1 year).
- Bilateral hearing of high tone Fletcher Index \< 60 dB
- Willingness to participate in this study (informed consent)
You may not qualify if:
- Anatomic cause of tinnitus (e.g. vestibular schwannoma, tumour, middle-ear pathology)
- DSM-V psychiatric disorders, other than depression or anxiety disorder (such as bipolar disorder, dementia, addiction, personality disorders); diagnosed by a psychiatrist. A psychiatrist will screen the patients for this matter.
- Depression or anxiety disorder which was already present before tinnitus. A psychiatrist will screen the patients for this matter.
- Cognitive impairment (assessed with standard 'cognitive functioning battery test' questionnaires) or coping problems (CISS-21)
- Active ear diseases that needs further attention according to research team
- Pregnancy or breast-feeding
- Active suicide thoughts or attempts
- Underlying malignancies, whenever life expectancy is lower than 2 years
- Other implantable electronic devices that potentially could interfere with DBS, e.g. cochlear implants, auditory brainstem implants or cortical implants
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MUMC+
Maastricht, 6229HX, Netherlands
Related Publications (1)
van Zwieten G, Devos JVP, Kotz SA, Ackermans L, Brinkmann P, Dauven L, George ELJ, Janssen AML, Kremer B, Leue C, Schwartze M, Temel Y, Smit JV, Janssen MLF. A Protocol to Investigate Deep Brain Stimulation for Refractory Tinnitus: From Rat Model to the Set-Up of a Human Pilot Study. Audiol Res. 2022 Dec 31;13(1):49-63. doi: 10.3390/audiolres13010005.
PMID: 36648926DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Janssen, Dr.
Maastricht University Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 7, 2019
First Posted
June 6, 2019
Study Start
January 6, 2021
Primary Completion
January 10, 2024
Study Completion
December 10, 2024
Last Updated
July 18, 2025
Record last verified: 2025-07